[Use of fluticasone/umeclidinium/vilanterol in France: A population based study].

IF 0.5 4区医学 Q4 RESPIRATORY SYSTEM

Revue des maladies respiratoires Pub Date : 2025-06-18 DOI:10.1016/j.rmr.2025.05.003

B Aguilaniu, J Cittee, L Watier, C Pribil, G Nachbaur, L Saïl, A Schmidt, A Panes, G Jebrak

{"title":"[Use of fluticasone/umeclidinium/vilanterol in France: A population based study].","authors":"B Aguilaniu, J Cittee, L Watier, C Pribil, G Nachbaur, L Saïl, A Schmidt, A Panes, G Jebrak","doi":"10.1016/j.rmr.2025.05.003","DOIUrl":null,"url":null,"abstract":"Introduction: In France, the fixed combination fluticasone/umeclidinium/vilanterol (FF/UMEC/VI) is prescribed for the treatment of moderate to severe COPD in adults not adequately treated by LABA/LAMA or ICS/LABA dual therapy since 2018. The aim of our study was to describe the characteristics, prescribing trajectories and care pathways of patients prior to their first prescription of FF/UMEC/VI in France.Methods: A retrospective cohort study included all patients aged over 40years with a first prescription of FF/UMEC/VI between 2018 and 2019 in France using data from the SNDS database. Descriptive analysis were conducted in the 3years preceding initiation of this medication.Results: Of the 34,906 patients included, 92% had received a prescription for dual or triple therapy in the 3years prior to starting FF/UMEC/VI. The mean age at inclusion was 69, with a majority of men. A description of the care pathway showed that 68% of patients had moderate exacerbations and 25% had severe exacerbations leading to hospitalization.Conclusions: Our results demonstrate that triple inhaled therapy with FF/UMEC/VI is used in accordance with its marketing authorization in France in the vast majority of cases.","PeriodicalId":21548,"journal":{"name":"Revue des maladies respiratoires","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue des maladies respiratoires","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.rmr.2025.05.003","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In France, the fixed combination fluticasone/umeclidinium/vilanterol (FF/UMEC/VI) is prescribed for the treatment of moderate to severe COPD in adults not adequately treated by LABA/LAMA or ICS/LABA dual therapy since 2018. The aim of our study was to describe the characteristics, prescribing trajectories and care pathways of patients prior to their first prescription of FF/UMEC/VI in France.

Methods: A retrospective cohort study included all patients aged over 40years with a first prescription of FF/UMEC/VI between 2018 and 2019 in France using data from the SNDS database. Descriptive analysis were conducted in the 3years preceding initiation of this medication.

Results: Of the 34,906 patients included, 92% had received a prescription for dual or triple therapy in the 3years prior to starting FF/UMEC/VI. The mean age at inclusion was 69, with a majority of men. A description of the care pathway showed that 68% of patients had moderate exacerbations and 25% had severe exacerbations leading to hospitalization.

Conclusions: Our results demonstrate that triple inhaled therapy with FF/UMEC/VI is used in accordance with its marketing authorization in France in the vast majority of cases.

查看原文本刊更多论文

[氟替卡松/乌莫替啶/维兰特罗在法国的使用：一项基于人群的研究]。

在法国，自2018年以来，fluticasone/umeclidinium/vilanterol （FF/UMEC/VI）固定联合用于治疗未充分接受LABA/LAMA或ICS/LABA双重治疗的成人中至重度COPD。本研究的目的是描述法国患者首次开FF/UMEC/VI处方前的特征、处方轨迹和护理途径。方法：一项回顾性队列研究纳入了2018年至2019年在法国首次处方FF/UMEC/VI的所有40岁以上患者，数据来自SNDS数据库。描述性分析在开始用药前3年进行。结果：在纳入的34906例患者中，92%的患者在开始FF/UMEC/VI治疗前的3年内接受过双联或三联治疗处方。入选的平均年龄为69岁，其中大多数是男性。对护理途径的描述显示68%的患者出现中度恶化，25%的患者出现严重恶化导致住院。结论：我们的研究结果表明，在绝大多数病例中，FF/UMEC/VI的三联吸入治疗是按照其在法国的上市许可使用的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revue des maladies respiratoires 医学-呼吸系统

CiteScore

1.10

自引率

16.70%

发文量

168

审稿时长

4-8 weeks

期刊介绍： La Revue des Maladies Respiratoires est l''organe officiel d''expression scientifique de la Société de Pneumologie de Langue Française (SPLF). Il s''agit d''un média professionnel francophone, à vocation internationale et accessible ici. La Revue des Maladies Respiratoires est un outil de formation professionnelle post-universitaire pour l''ensemble de la communauté pneumologique francophone. Elle publie sur son site différentes variétés d''articles scientifiques concernant la Pneumologie : - Editoriaux, - Articles originaux, - Revues générales, - Articles de synthèses, - Recommandations d''experts et textes de consensus, - Séries thématiques, - Cas cliniques, - Articles « images et diagnostics », - Fiches techniques, - Lettres à la rédaction.